RT Journal Article
SR Electronic
T1 Trends in Phase II trials for cancer therapies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.08.20245886
DO 10.1101/2020.12.08.20245886
A1 Azam, Faruque
A1 Vazquez, Alexei
YR 2020
UL http://medrxiv.org/content/early/2020/12/09/2020.12.08.20245886.1.abstract
AB Background Drug combinations are the standard of care in cancer treatment. Identifying effective cancer drug combinations has become more challenging because of the increasing number of drugs. However, a substantial number of cancer drugs stumble at Phase III clinical trials despite exhibiting favourable efficacy in the earlier Phase.Methods We analysed recent Phase II cancer trials comprising 2,165 response rates to uncover trends in cancer therapies and used a null model of non-interacting agents to infer synergistic and antagonistic drug combinations. We compared our latest efficacy dataset with a previous dataset to assess the progress of cancer therapy.Results We demonstrate that targeted therapies should be used in combination with cytotoxic drugs to reach high response rates. We identify 4 synergistic and 10 antagonistic combinations based on the observed and expected response rates. We also demonstrate that recent targeted agents have not significantly increased the response rates.Conclusions We conclude either we are not making progress or response rate measured by tumour shrinkage is not a reliable surrogate endpoint for the targeted agents.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Cancer Research UK C596/A21140 awarded to AV and A17196 (core funding to the CRUK Beatson Institute).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable to our study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCollected data on response rates is submitted in a supplementary file.